Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00104442 · ClinicalTrials.gov registry record · Phase 4
Study of the Effects of Current Drug Treatments on Levels of Certain Brain Chemicals in Alzheimer's Disease
A Phase 4 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 4
- Development phase
- 80
- Enrollment target
NCT00104442 is a Phase 4 study that has completed, run by Novartis. The registered enrollment target is 80 participants.
The verdict
NCT00104442, a Phase 4 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 80 participants
- Enrollment target
Study Summary
Alzheimer's disease is a medical illness that damages the brain and causes problems with memory, mood and behavior. A substance called acetylcholine (ACh), which is naturally produced in the body, plays an important role in the normal functioning of the brain. In subjects with Alzheimer's disease, the level of ACh is greatly reduced. Currently, there are three commonly prescribed drugs used for treating the symptoms of Alzheimer's disease by helping to maintain the level of ACh in the brain. This study will evaluate how much each of these drugs changes the levels of certain brain chemicals that are known to, or may play an important role in, Alzheimer's disease and its symptoms.
Interventions
- DRUG Rivastigmine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2003-10 |
| Est. Completion | 2006-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00104442
The ClinicalTrials.gov registry entry for NCT00104442 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rivastigmine is the first listed.
NCT00104442 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00104442 about?
NCT00104442 is a clinical study titled "Study of the Effects of Current Drug Treatments on Levels of Certain Brain Chemicals in Alzheimer's Disease". Alzheimer's disease is a medical illness that damages the brain and causes problems with memory, mood and behavior. A substance called acetylcholine (ACh), which is naturally produced in the body, plays an important role in the normal functioning of the brain. In subjects with Alzheimer's disease, t...
What is the current status of trial NCT00104442?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 80 participants. The study started on 2003-10. Estimated completion is 2006-04.
What interventions are being tested in trial NCT00104442?
The interventions under investigation include: Rivastigmine (DRUG).
Who is sponsoring clinical trial NCT00104442?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.